Clinical Trials
Closed
Phase
Accrual
75%
Published
SWOG Clinical Trial Number
S0327
A Phase II Trial of PS-341 (NSC-681239) in Patients with Platinum-Treated Extensive Stage Small Cell Lung Cancer.
Research Committee(s)
Lung Cancer
Activated
09-01-2003
Closed
09-15-2004
Closed
Phase
Accrual
25%
SWOG Clinical Trial Number
S0322
Single Agent ZD-1839 in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger), Pharmacology.
Research Committee(s)
Early Therapeutics & Rare Cancers
Head and Neck Cancer
Lung Cancer
Activated
08-15-2003
Closed
02-15-2005
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0306
Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium
Research Committee(s)
Genitourinary Cancer
Activated
07-15-2003
Closed
02-01-2007
Closed
Phase
Accrual
92%
Published
SWOG Clinical Trial Number
S0220
A Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors)
Research Committee(s)
Lung Cancer
Activated
07-01-2003
Closed
10-01-2007
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0317
A Phase II Study of OSI-774 (NSC-718781) in Patients with Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer
Research Committee(s)
Genitourinary Cancer
Activated
05-01-2003
Closed
12-15-2005
Closed
Phase
Accrual
60%
SWOG Clinical Trial Number
S0117
A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg™) and Standard Dose Ara-C for Patients With Relapsed Acute Myeloid Leukemia (AML)
Research Committee(s)
Leukemia
Activated
04-01-2003
Closed
10-15-2005
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S0227
Phase III Randomized Trial of Cisplatin/Paclitaxel Versus Cisplatin/Gemcitabine in Recurrent, Persistent or Metastatic Carcinoma of the Cervix
Research Committee(s)
Gynecologic Cancer
Activated
04-01-2003
Closed
07-28-2003
Closed
Phase
Accrual
10%
SWOG Clinical Trial Number
S0125
A Phase II Study of Chimerism-Mediated Immunotherapy (CMI) Using Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation in Older Patients With Acute Myeloid Leukemia (AML) in First Complete Remission (A BMT Study)
Research Committee(s)
Leukemia
Activated
04-01-2003
Closed
06-01-2005
Closed
Phase
Accrual
22%
Published
SWOG Clinical Trial Number
S0011
Phase II Trial of Surgery with Perioperative INGN 201 (Ad5CMV-p53) Gene Therapy Followed by Chemoradiotherapy for Advanced, Resectable Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx and Larynx
Research Committee(s)
Head and Neck Cancer
Activated
03-01-2003
Closed
07-01-2006
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0216
Docetaxel (NSC-628503), Cisplatin (NSC-119875), and 5-Fluorouracil (NSC-19893) Induction Chemotherapy Followed by Accerlerated Fractionation/Concomitant Boost Radiation and Concurrent Single Agent Cisplatin (NSC-119875), in Patients with Advanced Squamous Cell Head and Neck Cancer
Research Committee(s)
Head and Neck Cancer
Activated
03-01-2003
Closed
08-19-2004
Closed
Phase
Accrual
5%
SWOG Clinical Trial Number
S0025
Phase II Trial of Irinotecan (Camptosar) for Patients with Platinum and Taxane Refractory Ovarian, Peritoneal or Fallopian Tube Cancer
Research Committee(s)
Gynecologic Cancer
Activated
02-15-2003
Closed
08-15-2003
Closed
Phase
Accrual
48%
Published
SWOG Clinical Trial Number
S0030
Protocol for Assessment of Capecitabine for Advanced Colorectal Cancer in Patients Aged 70 Years and Older (and in a Cohort of Patients Younger than 60 Years)
Research Committee(s)
Gastrointestinal Cancer
Activated
02-01-2003
Closed
02-01-2005
Closed
Phase
Accrual
81%
Published
SWOG Clinical Trial Number
S0219
A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin with Molecular Correlates
Research Committee(s)
Genitourinary Cancer
Activated
01-01-2003
Closed
12-15-2006
Closed
Phase
Accrual
10%
SWOG Clinical Trial Number
S0122
Phase II Trial of Patients with Limited Stage Small Cell Lung Cancer Treated with Thoracic Radiation Therapy and Chemotherapy with Cisplatin/Etoposide Followed by Cisplatin/Etoposide and Anti-Idiotype Monoclonal Antibody Vaccines
Research Committee(s)
Lung Cancer
Activated
12-15-2002
Closed
05-15-2003
Closed
Phase
Accrual
9%
SWOG Clinical Trial Number
S0121
Phase II Evaluation of Carboplatin, Paclitaxel and Gemcitabine Followed by Concurrent Cisplatin and Radiation Therapy in Patients with Locally Advanced or Recurrent Urothelial Malignancy
Research Committee(s)
Genitourinary Cancer
Activated
11-15-2002
Closed
06-01-2005
Closed
Phase
Accrual
99%
Published
SWOG Clinical Trial Number
S0124
Randomized Phase III Trial of Cisplatin and Irinotecan versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
11-01-2002
Closed
03-01-2007
Closed
Phase
Accrual
47%
SWOG Clinical Trial Number
S0114
An Early Phase Study of an EGFRvIII Peptide Based Vaccine in Patients With EGFRvIII Expressing Cancers
Research Committee(s)
Immunomolecular Therapeutics
Activated
11-01-2002
Closed
06-01-2006
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0213
Pilot Trial of Hyper-CVAD and Methotrexate/ARA C+ Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
10-01-2002
Closed
09-01-2006
Closed
Phase
Accrual
2%
SWOG Clinical Trial Number
S0116
A Phase II Trial of a D1/3-MAGE-3-His Fusion Protein (NSC-719274) with Adjuvant SB-AS02B (NSC-719275) for Patients with Selected Stage IV, M1a or M1b Metastatic Melanoma
Research Committee(s)
Melanoma
Activated
09-15-2002
Closed
02-15-2004
Closed
Phase
Accrual
84%
Published
SWOG Clinical Trial Number
S0215
Docetaxel and Vinorelbine Plus Filgrastim with Weekly Trastuzumab for HER-2 Positive, Stage IV Breast Cancer, Phase II Pilot
Research Committee(s)
Breast Cancer
Activated
09-15-2002
Closed
01-01-2007